HIMSS
24.4.2024 09:04:30 CEST | Business Wire | Press release
To address Europe’s most pressing healthcare challenges, Europe's longest-running, most influential digital health conference returns in 2024, bringing together innovators to shape tomorrow’s healthcare.
The HIMSS24 European Health Conference & Exhibition will occur from 29-31 May at the Centro Congressi Roma La Nuvola in Rome, Italy. The conference will be the epicenter for pan-European collaborations and innovation, featuring thought leaders and healthcare professionals working together to create the best technology solutions across the digital health landscape.
HIMSS24 Europe will feature programming focused on major global health challenges. Experts will lead discussions on how Europe uses data analytics, artificial intelligence, cybersecurity, and other cutting-edge technologies to address universal issues like health equity, patient privacy, access to care, workforce burnout, staffing shortages, and climate change.
Registration is open for HIMSS24 Europe, and interested journalists can contact HIMSS to receive complimentary press credentials. The conference will attract thousands of industry experts worldwide, including CIOs and CTOs, AI experts, cybersecurity leaders, data scientists, healthcare practitioners, and public health policy leaders.
“We’ve built an innovative programme that offers the tools and insights healthcare professionals need to transform systems and improve outcomes,” said Ronan O’Connor, Managing Director, EMEA and Vice President at HIMSS. “This year, we are proud to bring executives, policymakers, and healthcare professionals of all kinds together in Italy, which is a leader in digital health innovation.”
The program lineup includes a deep dive into Europe’s current regulatory landscape, including the AI Act, the European Health Data Space (EHDS), and the European Recovery and Resilience Fund. This year’s keynote speakers will lend their expertise to enrich discussions on pressing healthcare issues.
- Marco Marsella, director, Digital, EU4Health and Health Systems Modernisation and DG SANTE, European Commission.
- Hela Ghariani, co-head of the Digital Health Delegation, Ministry of Social Affairs and Health, France and co-chair of the EU eHealth Network.
- John Riggi, FBI veteran and national advisor for cybersecurity and risk at the American Hospital Association
- Sharon Allen, co-founder and chief executive officer of World Telehealth Initiative, a remote philanthropic model that allows physicians to provide sustainable medical expertise via telehealth.
- Dr. Waheed Arian, founder of Arian Wellbeing.
Emerging topics such as the ethical use of AI in healthcare and finding the balance between effective data sharing and protecting patient privacy will be top of mind for presenters and attendees.
The conference will showcase emerging healthcare solutions through Startup Pitchfest, offering a platform for innovative startups to address entrenched challenges faced by health systems and providers.
The conference programming is supported by a Programme Committee comprising 17 highly reputable and well-respected healthcare professionals from across Europe.
Networking opportunities and interactive experiences will also be at the forefront of HIMSS24 Europe, where attendees can connect with representatives from more than 70 countries representing the global health ecosystem.
Click here to learn more about HIMSS24 Europe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424984367/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom